Table 3.
Infectious and non-infectious complications among the two groups, n (%)
|
|
Total, 105
|
Non-transfusion, 51 (48.6%)
|
Transfusion, 54 (51.4%)
|
P value
|
| No. of infections | 0 (0-1) | 1 (0-1) | 0 (0-1.25) | 0.554 |
| Types of infections | ||||
| none | 55 (52.4) | 25 (49) | 30 (55.6) | 0.745 |
| UTI | 30 (28.6) | 14 (27.5) | 16 (29.6) | 0.832 |
| Pnemonia | 1 (1) | 1 (2) | 0 (0) | 0.486 |
| TB | 1 (1) | 0 (0) | 1 (1.9) | 1 |
| BK | 7 (6.7) | 5 (9.8) | 2 (3.7) | 0.261 |
| Bactremia | 4 (3.8) | 1 (2) | 3 (5.6) | 0.618 |
| Epidediymo-orchitis | 2 (1.9) | 1 (2) | 1 (1.9) | 1 |
| Gastroenteritis | 2 (1.9) | 2 (3.9) | 0 (0) | 0.234 |
| Herpes zoster | 1 (1) | 0 (0) | 1 (1.9) | 1 |
| Infected AVF | 1 (1) | 1 (2) | 0 (0) | 0.486 |
| Perianal abcess | 1 (1) | 1 (2) | 0 (0) | 0.486 |
| COVID-19 | 9 (8.6) | 6 (11.8) | 3 (5.6) | 0.311 |
| URTI | 2 (1.9) | 1 (2) | 1 (1.9) | 1 |
| CMV | 12 (11.4) | 6 (11.8) | 6 (11.1) | 1 |
| Urological complications | ||||
| None | 95 (90.5) | 49 (96.1) | 46 (85.2) | 0.484 |
| Allograft artery stenosis | 1 (1) | 0 (0) | 1 (1.9) | |
| Collection | 3 (2.9) | 1 (2) | 2 (3.7) | |
| Lymphocele | 1 (1) | 0 (0) | 1 (1.9) | |
| Obstrctive uropathy | 1 (1) | 0 (0) | 1 (1.9) | |
| Perinephric collection and ureteric stricture | 2 (1.9) | 0 (0) | 2 (3.7) | |
| Unrogenic bladder | 1 (1) | 0 (0) | 1 (1.9) | |
| Urinary leak | 1 (1) | 1 (2) | 0 (0) | |
| Urological complications | ||||
| No | 95 (90.5) | 49 (96.1) | 46 (85.2) | 0.094 |
| Yes | 10 (9.5) | 2 (3.9) | 8 (14.8) | |
| CNI withdrawal | 1 (1) | 0 (0) | 1 (1.9) | 1 |
| Duration from Tx | 3 d | |||
| MMF withdrawal | 1 (1) | 0 (0) | 1 (1.9) | 1 |
| Duration from Tx | 3 d | |||
| Steroids withdrawal | 0 (0) | 0 (0) | 0 (0) |
UTI: Urinary tract infection; TB: Tuberculosis; AVF: Arterio-venous fistula; COVID-19: Coronavirus disease 2019; URTI: Upper respiratory tract infection; CMV: Cytomegalovirus; CNI: Calcineurin inhibitor; MMF: Mycophenolate mofetil.